2020
DOI: 10.1111/cod.13667
|View full text |Cite
|
Sign up to set email alerts
|

Systemic allergic dermatitis from intra‐articular triamcinolone acetonide: Report of two cases with unusual clinical manifestations

Abstract: heart failure, renal dysfunction, and hepatic disease. 4 After oral administration, it is rapidly absorbed and is known for its high bioavailability. It inhibits NaCl reabsorption in the medullary portion of the thick ascending limb of the loop of Henle. 5 In comparison with equipotent doses of furosemide, it produces a more prolonged water and electrolyte diuresis, but does not increase kaliuresis to the same extent. 6 Torasemide is used widely in cardiology. Phototoxic skin reactions this loop diuretic may b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 9 publications
1
2
0
Order By: Relevance
“…The results of our study confirm that cross‐reactions between budesonide and other CSs are an issue 9,12,31‐35 . In fact, 16.7% of positive patch test reactions to budesonide were considered cross‐reactions, with the highest prevalence in the >70 age group.…”
Section: Discussionsupporting
confidence: 78%
See 1 more Smart Citation
“…The results of our study confirm that cross‐reactions between budesonide and other CSs are an issue 9,12,31‐35 . In fact, 16.7% of positive patch test reactions to budesonide were considered cross‐reactions, with the highest prevalence in the >70 age group.…”
Section: Discussionsupporting
confidence: 78%
“…The results of our study confirm that cross-reactions between budesonide and other CSs are an issue. 9,12,[31][32][33][34][35] In fact, 16.7% of positive patch test reactions to budesonide were considered cross-reactions, with the highest prevalence in the >70 age group. These patients never used this CS, and patch tests were positive, with clinical relevance to topical and systemic CSs, as described by Baeck et al: 33 Group 1 in 60.0% (hydrocortisone 17-butyrate 8, methylprednisolone 1); Group 2 in 13.3% (halcinonide 1, triamcinolone acetonide 1); and Group 3 in 26.7% (clobetasol propionate 3, dexamethasone 1).…”
Section: Discussionmentioning
confidence: 99%
“…CSs were first used in the 1950s in the first case of ACD, and nowadays, they represent the cornerstone of the treatment of ACD, but they can paradoxically cause ACD themselves (52). CS hypersensitivity is a challenging issue, especially in choosing an alternative and safe topical and systemic CS, due to the high frequency of cross-reactions among CS groups (71)(72)(73)(74). The molecular structure and configuration of CSs were studied and classified by Baeck (71) into three different groups.…”
Section: Topical Medicationsmentioning
confidence: 99%